Jeff Yass’s Protagenic Therapeutics Warrant PTIXW Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-87,596
| Closed | -$2.71K | – | 13915 |
|
|
2025
Q4 | $2.71K | Hold |
87,596
| – | – | ﹤0.01% | 12118 |
|
|
2025
Q3 | $2.24K | Buy |
87,596
+62,218
| +245% | +$2.98K | ﹤0.01% | 12165 |
|
|
2025
Q2 | $1.45K | Sell |
25,378
-24,806
| -49% | -$895 | ﹤0.01% | 12502 |
|
|
2025
Q1 | $376 | Sell |
50,184
-16,989
| -25% | -$87 | ﹤0.01% | 12347 |
|
|
2024
Q4 | $302 | Buy |
67,173
+20,558
| +44% | +$183 | ﹤0.01% | 12061 |
|
|
2024
Q3 | $420 | Buy |
46,615
+20,015
| +75% | +$228 | ﹤0.01% | 11829 |
|
|
2024
Q2 | $218 | Buy |
+26,600
| New | +$537 | ﹤0.01% | 11900 |
|
|
2023
Q3 | – | Sell |
-11,327
| Closed | -$379 | – | 12768 |
|
|
2023
Q2 | $379 | Sell |
11,327
-4,184
| -27% | -$131 | ﹤0.01% | 11925 |
|
|
2023
Q1 | $372 | Sell |
15,511
-8,453
| -35% | -$438 | ﹤0.01% | 12441 |
|
|
2022
Q4 | $527 | Buy |
23,964
+4,124
| +21% | +$151 | ﹤0.01% | 12210 |
|
|
2022
Q3 | $1K | Sell |
19,840
-6,879
| -26% | -$534 | ﹤0.01% | 12990 |
|
|
2022
Q2 | $4K | Buy |
+26,719
| New | +$3.46K | ﹤0.01% | 12626 |
|
Jeff Yass's PTIXW Position: Q1 2026 in Review
Jeff Yass sold out of Protagenic Therapeutics Warrant (PTIXW) in Q1 2026, closing a stake of 87,596 shares — an estimated $2.71K sold.
Jeff Yass first reported a position in PTIXW in Q2 2022 and held it in 12 quarters. The position peaked at $4K in Q2 2022. 0 funds tracked by Wall St. Rank hold PTIXW as of Q1 2026.
- Jeff Yass reported no remaining Protagenic Therapeutics Warrant position as of Q1 2026 after selling out during the quarter.
- Jeff Yass sold 87,596 Protagenic Therapeutics Warrant shares in Q1 2026, an estimated $2.71K.
- Jeff Yass first reported a position in Protagenic Therapeutics Warrant in Q2 2022 and held it in 12 quarters.
- Jeff Yass's Protagenic Therapeutics Warrant position peaked at $4K in Q2 2022.
- 0 funds tracked by Wall St. Rank held Protagenic Therapeutics Warrant as of Q1 2026.
Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.